Dysport 300 IU

Dysport® 300 IU is a prescription injectable medication containing 300 International Units (IU) of abobotulinumtoxinA, a botulinum toxin type A used in aesthetic medicine and various medical specialties. It is designed to temporarily reduce muscle activity, helping improve the appearance of dynamic facial wrinkles and treat certain neuromuscular disorders. Dysport should only be administered by qualified healthcare professionals trained in botulinum toxin injection techniques. The active ingredient is: Dysport Dysport 300 IU is supplied as a sterile, lyophilized (freeze-dried) powder in a single-use vial. Before administration, it is reconstituted with preservative-free sterile saline according to the manufacturer’s instructions. The product is intended for professional use only, with dosage and injection sites determined by the healthcare provider based on the patient’s condition and treatment goals.

Composition

Each vial typically contains:

• 300 International Units (IU) of abobotulinumtoxinA
• Human serum albumin
• Lactose monohydrate

The formulation is preservative-free and intended for single-patient use after reconstitution.

Storage Requirements

To preserve product quality:

• Store refrigerated according to the manufacturer’s labeling.
• Protect from excessive heat and direct sunlight.
• Reconstitute only with preservative-free sterile saline.
• Use the reconstituted solution within the recommended timeframe.
• Maintain aseptic handling procedures.

Safety Information

Dysport is a prescription medication and should only be administered by qualified healthcare professionals.

It may not be appropriate for individuals with:

• Known hypersensitivity to any component of the formulation
• Infection at the intended injection site
• Certain neuromuscular disorders

Possible side effects include:

• Injection-site pain or bruising
• Headache
• Temporary eyelid drooping
• Muscle weakness
• Swelling or redness at the injection site

Serious adverse reactions, including difficulty swallowing, speaking, or breathing, are uncommon but require immediate medical attention.

Mechanism of Action

Dysport works by temporarily blocking the release of acetylcholine at the neuromuscular junction, reducing the ability of targeted muscles to contract.

This results in:

• Temporary muscle relaxation
• Reduction of dynamic facial wrinkles
• Decreased involuntary muscle contractions
• Relief of symptoms associated with certain neurological disorders

Product Features

• 300 IU potency per vial
• Contains purified abobotulinumtoxinA
• Sterile lyophilized powder
• Precise dosing by trained healthcare professionals
• Suitable for approved aesthetic and therapeutic applications
• Single-use vial

1. Minimally Invasive

Provides wrinkle reduction and therapeutic benefits without surgery.

2. Fast Onset

Many patients begin to notice improvements within a few days.

3. Clinically Established

Widely used for approved medical and cosmetic indications.

4. Temporary Results

Effects gradually wear off, allowing individualized retreatment schedules.

5. Broad Clinical Applications

Used in dermatology, neurology, rehabilitation medicine, ophthalmology, and other medical specialties.

Cosmetic Uses

Depending on local regulatory approvals, Dysport may be used to temporarily improve the appearance of:

• Glabellar (frown) lines
• Forehead lines
• Crow’s feet
• Other dynamic facial wrinkles as determined by a qualified healthcare professional

Medical Uses

Depending on country-specific approvals, Dysport may also be prescribed for:

• Cervical dystonia
• Upper and lower limb spasticity
• Blepharospasm
• Hemifacial spasm
• Pediatric spasticity associated with cerebral palsy
• Other approved neuromuscular disorders

Approved indications vary by country and regulatory authority.

Typical Duration of Effect

Treatment results vary depending on the indication, dosage, and individual response.

Typical cosmetic outcomes include:

• Initial improvement within 2–3 days
• Full effect within approximately 1–2 weeks
• Duration of approximately 3–5 months, depending on the treatment area and patient characteristics